Sökning: onr:"swepub:oai:DiVA.org:oru-105110" >
Ustekinumab Versus ...
-
Eriksson, Carl,1981-Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
(författare)
Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease
- Artikel/kapitelEngelska2023
Förlag, utgivningsår, omfång ...
-
2023-03-17
-
Springer-Verlag New York,2023
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:oru-105110
-
https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-105110URI
-
https://doi.org/10.1007/s10620-023-07897-2DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:152296734URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Funding agencies:Johnson & Johnson USA Janssen Biotech Inc CNTO1275CRD0005Stockholm Region Clinical Postdoctoral Researcher GrantStrategic Research Area Epidemiology program at Karolinska Institutet
-
BACKGROUND: There are little data on positioning biologics in Crohn's disease (CD). AIMS: We aimed to assess the comparative effectiveness and safety of ustekinumab vs tumour necrosis factor-alpha (anti-TNF) agents after first-line treatment with anti-TNF in CD.METHODS: We used Swedish nationwide registers to identify patients with CD, exposed to anti-TNF who initiated second-line biologic treatment with ustekinumab or second-line anti-TNF therapy. Nearest neighbour 1:1 propensity score matching (PSM) was used to balance the groups. The primary outcome was 3-year drug survival used as a proxy for effectiveness. Secondary outcomes included drug survival without hospital admission, CD-related surgery, antibiotics, hospitalization due to infection and exposure to corticosteroids.RESULTS: Some 312 patients remained after PSM. Drug survival at 3 years was 35% (95% CI 26-44%) in ustekinumab compared to 36% (95% CI 28-44%) in anti-TNF-treated patients (p = 0.72). No statistically significant differences were observed between the groups in 3-year survival without hospital admission (72% vs 70%, p = 0.99), surgery (87% vs 92%, p = 0.17), hospital admission due to infection (92% vs 92%, p = 0.31) or prescription of antibiotics (49% vs 50%, p = 0.56). The proportion of patients continuing second-line biologic therapy did not differ by reason for ending first-line anti-TNF (lack of response vs intolerance) or by type of first-line anti-TNF (adalimumab vs infliximab).CONCLUSION: Based on data from Swedish routine care, no clinically relevant differences in effectiveness or safety of second-line ustekinumab vs anti-TNF treatment were observed in patients with CD with prior exposure to anti-TNF.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Söderling, JonasKarolinska Institutet
(författare)
-
Karlqvist, Sara,1992-Örebro universitet,Institutionen för medicinska vetenskaper,Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden(Swepub:oru)srt
(författare)
-
Bröms, GabriellaKarolinska Institutet
(författare)
-
Everhov, Åsa H.Karolinska Institutet
(författare)
-
Bergemalm, Daniel,1977-Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Gastroenterology(Swepub:oru)dbm
(författare)
-
Ludvigsson, Jonas F.,1969-Karolinska Institutet(Swepub:oru)jsln
(författare)
-
Olén, OlaKarolinska Institutet
(författare)
-
Halfvarson, Jonas,1970-Örebro universitet,Institutionen för medicinska vetenskaper,Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden(Swepub:oru)jshn
(författare)
-
SWIBREG study group, -
(bidragsgivare)
-
Örebro universitetInstitutionen för medicinska vetenskaper
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Digestive Diseases and Sciences: Springer-Verlag New York68:7, s. 3119-31280163-21161573-2568
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Eriksson, Carl, ...
-
Söderling, Jonas
-
Karlqvist, Sara, ...
-
Bröms, Gabriella
-
Everhov, Åsa H.
-
Bergemalm, Danie ...
-
visa fler...
-
Ludvigsson, Jona ...
-
Olén, Ola
-
Halfvarson, Jona ...
-
SWIBREG study gr ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Gastroenterologi
- Artiklar i publikationen
-
Digestive Diseas ...
- Av lärosätet
-
Örebro universitet
-
Karolinska Institutet